RxDoctor Payments Data

Terry Harvey

Family · Cumberland, MDNPI 1225079098

Payments from drug & device makers

$1,212in general payments, 2019–2025

Across 23 payments — averaging $52.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$340
  • Phathom Pharmaceuticals, Inc.$244
  • Johnson & Johnson$220
  • Astellas Pharma US Inc$100
  • Medtronic$57
  • Neurocrine Biosciences, Inc.$51
  • plus $200 from 7 others

What the payments were for

  • Food & beverage$1,11292%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,212 in reported general payments places this provider in the 70th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$845
Medicare patients
74
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$138,863
EliquisApixaban67$62,373
JanuviaSitagliptin Phosphate54$50,658
Tresiba Flextouch U-200Insulin Degludec16$32,778
MyrbetriqMirabegron35$25,898
ProliaDenosumab15$24,830
XareltoRivaroxaban17$24,435
Tresiba Flextouch U-100Insulin Degludec21$23,735
JardianceEmpagliflozin17$21,474
Breo ElliptaFluticasone/Vilanterol32$16,585
TradjentaLinagliptin16$16,397
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$9,055
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$5,756
Pravastatin Sodium260$4,645
Levothyroxine Sodium435$3,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$100$25,89835 claims
Johnson & JohnsonXarelto$220$24,43517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,843 family providers in Maryland.

Other family in Cumberland

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →